

THE SENATE
THE THIRTIETH LEGISLATURE
REGULAR SESSION OF 2020

COMMITTEE ON COMMERCE, CONSUMER PROTECTION, AND HEALTH

Senator Rosalyn H. Baker, Chair
Senator Stanley Chang, Vice-Chair

MEASURES DEFERRED TO FRIDAY, FEBRUARY 7, 2020

DATE: Friday, February 7, 2020
TIME: 9:30 AM
PLACE: Conference Room 229
State Capitol
415 South Beretania Street

DECISION MAKING ON THE FOLLOWING MEASURE(S):

SB2462 Status and Testimony	RELATING TO CONTROLLED SUBSTANCES. Requires, by September 1, 2020, that the department of health request the Drug Enforcement Administration to grant a federal schedule I exemption for the medical use of cannabis in Hawaii.	CPH, JDC
SB2226 Status and Testimony	RELATING TO PHARMACY BENEFIT MANAGERS. Establishes business practice and transparency reporting requirements for pharmacy benefit managers. Replaces the registration requirement for pharmacy benefit managers with a licensing requirement. Increases penalties for violations of the pharmacy benefit managers law. Effective 1/1/2021.	CPH, JDC
SB2280 Status and Testimony	RELATING TO PHARMACY BENEFIT MANAGERS. Prohibits pharmacy benefit managers from engaging in self-serving business practices. Replaces registration requirement with license requirement for pharmacy benefit managers. Increases pharmacy benefit manager reporting requirements to the insurance commissioner. Increases application and renewal fees and penalties for failure to renew a license.	CPH, JDC

SB2276 Status and Testimony	RELATING TO PRESCRIPTION DRUGS. Requires drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers if a proposed increase in the wholesale price of certain drugs would result in a sixteen per cent or more price increase over a two year period. Requires the drug manufacturer to identify and report to the insurance commissioner information on certain drugs whose wholesale acquisition cost increases by a certain amount during a specified time frame. Imposes fines.	CPH, JDC
SB2582 Status and Testimony	RELATING TO HEALTH. Authorizes advanced practice registered nurses, in addition to physicians, to practice medical aid in dying in accordance with their scope of practice and prescribing authority. Reduces the mandatory waiting period between oral requests from twenty days to fifteen days. Waives the mandatory waiting period for those terminally ill individuals not expected to survive the mandatory waiting period.	CPH, JDC
SB2278 Status and Testimony	RELATING TO HEALTH INSURANCE. Establishes disclosure and consent requirements for nonparticipating health care providers. Prohibits nonparticipating health care providers from balance billing patients in specific circumstances. Establishes rate calculation requirements for reimbursement of nonparticipating providers.	CPH, JDC
SB2539 Status and Testimony	RELATING TO HEALTH CARE. Requires health insurers, mutual benefit societies, and health maintenance organizations to provide coverage for a comprehensive category of reproductive health services, drugs, devices, products, and procedures. Prohibits discrimination in the provision of reproductive health care services. Effective 3/15/2021.	CPH, JDC

No testimony will be accepted.

FOR AMENDED NOTICES: Measures that have been deleted are stricken through and measures that have been added are underscored. If a measure is both underscored and stricken through, that measure has been deleted from the agenda.

FOR FURTHER INFORMATION, PLEASE CONTACT THE COMMITTEE CLERK AT 808-586-6070.